XSHG
600513
Market cap707mUSD
Oct 09, Last price
16.28CNY
1D
-1.93%
1Q
5.10%
Jan 2017
21.21%
IPO
420.49%
Name
JIANGSU LIANHUAN PHARMACEUTICAL CO. LTD
Chart & performance
P/E
—
P/S
1.71
EPS
—
Div yield, %
0.54%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
14.37%
Revenues
2.71b
+25.52%
Net income
-98m
L
CFO
-14m
L
Dividend
Jul 08, 20260.07 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jiangsu Lianhuan Pharmaceutical Co., Ltd. operates within China, specializing in the production and distribution of chemical raw materials, pharmaceutical formulations, and organic intermediate compounds. Its extensive product range addresses diverse therapeutic needs, including cardiovascular issues, allergies, urinary tract conditions, infectious diseases, and immune system modulation. The enterprise was founded in 2000 and has its principal headquarters located in Yangzhou, China.
Key people
Aixin Wang
Chief Financial Officer · since 2007
Wenge Wu
General Manager, Director · since 2016
Heping Pan
Deputy General Manager · since 2018
Jun Zhou
Deputy General Manager · since 2001
Zhiyuan Lu
Director · since 2004
Jian Wu
Director · since 2004
Chunlai Xia
Chairman of the Board · since 2016
Yingqi Gu
Independent Director · since 2009
Yuechun Zhao
Independent Director · since 2011
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||